Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07567001 · ClinicalTrials.gov registry record · Phase 3
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 5,610
- Enrollment target
NCT07567001: Recruiting Phase 3 study, sponsored by Novo Nordisk A/S.
NCT07567001 is a Phase 3 study that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 5,610 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (627% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07567001, a Phase 3 study, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 5,610 participants
- Enrollment target
Study Summary
This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have HFpEF or HFmrEF and excess body weight. Participants will get NNC0487-0111 or placebo by injection once a week. Which treatment participants get is decided by chance. NNC0487-0111 is a new medicine that doctors cannot prescribe yet, but it has been tested in people before.
Primary Outcome
Measured in days.
Interventions
- DRUG Placebo
- DRUG NNC0487-0111
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,610 participants |
| Start Date | 2026-05-11 |
| Est. Completion | 2029-08-15 |
| Phase | Phase 3 |
What NCT07567001 shows while recruiting
NCT07567001 is an interventional study that assigns participants to a tested intervention. Its 5,610 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (627% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07567001 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07567001 about?
NCT07567001 is a clinical study titled "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity". This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to fi...
What is the current status of trial NCT07567001?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 5,610 participants. The study started on 2026-05-11. Estimated completion is 2029-08-15.
What interventions are being tested in trial NCT07567001?
The interventions under investigation include: Placebo (DRUG), NNC0487-0111 (DRUG).
Who is sponsoring clinical trial NCT07567001?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07567001's enrollment target sits among peer trials
5,610 43rd of 2000 higher than 1,958 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05636176 · 5,600 participants · Phase 3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
- NCT06627335 · 5,621 participants
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
- NCT06981598 · 5,586 participants · NA
Prevention of Psychological Health Problems Via Integrated Operational Support
- NCT07146568 · 5,515 participants · NA
Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hospital
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI